

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except share and per share data)

	Three Months Ended March 31,	
	2019	2018
Grant and collaboration revenues	\$ 364	\$ 221
Operating expenses:		
Research and development	556	487
General and administrative	510	357
	1,066	844
Loss from operations	(702)	(623)
Other income (expense), net	1	1
Net loss	\$ (701)	\$ (622)
Net loss per common share	\$ (1.43)	\$ (2.50)
Weighted average common shares outstanding	491,707	248,340

Condensed Consolidated Balance Sheet Information
(amounts in thousands)

	March 31, 2019	Dec. 31, 2018
Assets:		
Cash and cash equivalents	\$ 176	\$ 260
Other current assets	272	360
Total current assets	448	620
Property, net	14	11
Other assets	11	11
Total assets	\$ 473	\$ 642
Liabilities and stockholders' equity (deficiency)		
Current liabilities	\$ 1,645	\$ 1,624
Note payable, net of current portion	35	40
Stockholders' equity (deficiency)	(1,207)	(1,022)
Total liabilities and stockholders' equity (deficiency)	\$ 473	\$ 642
Common Shares Outstanding	556,489	437,807